DOI:
10.1055/s-00000059
Pneumologie
LinksClose Window
References
Soria J.
Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial.
Lancet Oncol 2015;
16: 897-907
Search in:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.